Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 1001 to 1050 of 2486 results for term

  1. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

  2. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.

  3. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  4. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England

  5. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

  6. Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery (TA157)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery in adults.

  7. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.

  8. Decision making and mental capacity (QS194)

    This quality standard covers decision making in people aged 16 and over, using health and social care services who may lack capacity to make their own decisions (now or in the future). It aims to support implementation of the aims and principles of the Mental Capacity Act 2005 and relevant Codes of Practice. It is not a substitute for these.

  9. Medicines management in care homes (QS85)

    This quality standard covers managing medicines safely and effectively in care homes. It includes processes for prescribing, handling and administering medicines for adults, young people, and children living in care homes. It also includes providing care and support relating to medicines. It describes high-quality care in priority areas for improvement.

  10. Radiofrequency tissue reduction for turbinate hypertrophy (HTG343)

    Evidence-based recommendations on radiofrequency tissue reduction for turbinate hypertrophy. This involves using radiofrequency energy to close blood vessels that can cause swelling and destroy excess tissue.

  11. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

  12. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

  13. Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)

    Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.

  14. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

  15. Tobacco: treating dependence (QS207)

    This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.

  16. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  17. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

  18. Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

    Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

  19. Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

    Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

  20. Inflammatory bowel disease (QS81)

    This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.

  21. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

  22. Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica (HTG398)

    Evidence-based recommendations on percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica. This involves delivering heat energy to the damaged disc annulus.

  23. Brolucizumab for treating wet age-related macular degeneration (TA672)

    Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

  24. Joint distraction for knee osteoarthritis without alignment correction (HTG381)

    Evidence-based recommendations on joint distraction for knee osteoarthritis without alignment correction. This involves fixing a metal frame around the knee to take weight off the joint and encourage the cartilage to repair itself.

  25. Gastroelectrical stimulation for gastroparesis (HTG341)

    Evidence-based recommendations on gastroelectrical stimulation for gastroparesis. This involves using a stimulating device to send electrical impulses to the stomach muscles to help them work normally.

  26. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

  27. Corneal endothelial transplantation (HTG195)

    Evidence-based recommendations on corneal endothelial transplantation. This involves replacing only the innermost layers of the cornea with a healthy section from a donor eye without disturbing the overall structure.

  28. Therapeutic endoscopic division of epidural adhesions (HTG210)

    Evidence-based recommendations on therapeutic endoscopic division of epidural adhesions. This involves separating epidural adhesions from the nerves or spinal cord through a small cut near the lower spine (keyhole surgery).

  29. Digital technologies for managing non-specific low back pain: early value assessment (HTG712)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.

  30. Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.

  31. Pressure ulcers (QS89)

    This quality standard covers preventing, assessing and managing pressure ulcers (bed sores) in adults, young people and children. It includes risk assessment and support to prevent pressure ulcers. It applies to all settings, including hospitals, care homes (with and without nursing care) and people’s own homes.

  32. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

    Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.

  33. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (TA1139)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.

  34. Oral health for adults in care homes (NG48)

    This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.

  35. Balloon cryoablation for squamous dysplasia of the oesophagus (HTG560)

    Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.

  36. Laparoscopic renal denervation for loin pain haematuria syndrome (HTG596)

    Evidence-based recommendations on laparoscopic renal denervation for loin pain haematuria syndrome in adults. This involves the stripping away of nerves from the kidney using keyhole surgery to relieve pain.

  37. Grenz rays therapy for inflammatory skin conditions (HTG151)

    Evidence-based recommendations on Grenz rays therapy for inflammatory skin conditions. This involves exposing the skin to low-energy, non-penetrative electromagnetic radiation.

  38. Uterine artery embolisation for fibroids (HTG240)

    Evidence-based recommendations on uterine artery embolisation for fibroids. This involves injecting small particles into the blood vessels that take blood to the uterus, via the groin.

  39. Endoscopic transsphenoidal pituitary adenoma resection (HTG14)

    Evidence-based recommendations on endoscopic transsphenoidal pituitary adenoma resection. This involves inserting a tube into the nostril towards the tumour base and removing the tumour using specialised surgical instruments.

  40. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

  41. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

    Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.

  42. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

    Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

  43. Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

    Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.